Celcuity Inc. (NASDAQ:CELC) Receives $29.17 Average Price Target from Brokerages

Shares of Celcuity Inc. (NASDAQ:CELC) have been assigned an average recommendation of “Buy” from the seven ratings firms that are presently covering the company, Marketbeat reports. Six analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $29.17.

CELC has been the topic of a number of recent research reports. Stifel Nicolaus increased their target price on Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Monday, October 7th. HC Wainwright reiterated a “buy” rating and set a $27.00 price objective on shares of Celcuity in a report on Friday, November 15th. Needham & Company LLC reissued a “buy” rating and set a $23.00 target price on shares of Celcuity in a research report on Friday, November 15th. Finally, Lifesci Capital began coverage on shares of Celcuity in a research report on Monday, August 26th. They issued an “outperform” rating and a $27.00 price target on the stock.

Celcuity Trading Up 3.8 %

Shares of Celcuity stock opened at $12.46 on Friday. The stock has a market capitalization of $462.64 million, a PE ratio of -4.77 and a beta of 0.74. Celcuity has a 52 week low of $11.51 and a 52 week high of $22.19. The stock has a 50 day moving average price of $14.08 and a two-hundred day moving average price of $15.39. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35.

Institutional Investors Weigh In On Celcuity

A number of institutional investors have recently added to or reduced their stakes in the company. nVerses Capital LLC purchased a new position in shares of Celcuity in the 3rd quarter worth approximately $33,000. Prospera Private Wealth LLC purchased a new position in Celcuity in the third quarter worth $35,000. Values First Advisors Inc. purchased a new position in Celcuity in the third quarter worth $86,000. Quest Partners LLC grew its stake in Celcuity by 31.3% in the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock valued at $95,000 after purchasing an additional 1,379 shares during the period. Finally, SG Americas Securities LLC purchased a new stake in shares of Celcuity during the 3rd quarter valued at $119,000. 63.33% of the stock is owned by institutional investors.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.